Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer

被引:27
|
作者
Monge, A
Jagla, M
Lapouge, G
Sasorith, S
Cruchant, M
Wurtz, JM
Jacqmin, D
Bergerat, JP
Céraline, J
机构
[1] Univ Strasbourg 1, Lab Cancerol Expt & Radiobiol, EA 3430, IRCAD, F-67091 Strasbourg, France
[2] IGBMC, Dept Biol & Genom Struct, Illkirch Graffenstaden, France
[3] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France
[4] Hop Univ Strasbourg, Serv Chirurg Urol, Strasbourg, France
关键词
androgen receptor; hormone-refractory prostate cancer; mutation; DNA binding specificity; transcriptional activity;
D O I
10.1007/s00018-005-5471-y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Missense mutations in the androgen receptor (AR) contribute to the failure of hormonal therapy for prostate cancer (PCa), but the underlying molecular bases remain uncharacterized. Here, we describe a new AR variant found in a hormone-refractory metastatic PCa, in which threonine 575 in the DNA binding domain, and threonine 877 in the ligand-binding domain, were both replaced by an alanine. Using gene reporter assays, we demonstrate that the T575A mutation weakened transcriptional activity from promoters containing AR-spe-cific responsive elements, while activity from promoters with AR-non-specific elements was enhanced. Data from gel shift experiments revealed a preferential binding of the T575A mutant to AR-non-specific motifs. We demonstrate that the two mutations T575A and T877A cooperate to confer new functional properties on the AR, and that the mutant AR functions simultaneously as a promiscuous AR due to the T877A mutation, and an unfaithful AR due to the T575A mutation.
引用
收藏
页码:487 / 497
页数:11
相关论文
共 50 条
  • [41] Revolutions in the management of hormone-refractory prostate cancer
    Abrahamsson, PA
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 1 - 2
  • [42] Therapeutic options for hormone-refractory prostate cancer
    Miller, K.
    Boergermann, C.
    Thueroff, J.
    Albers, P.
    Wirth, M.
    UROLOGE, 2006, 45 (05): : 580 - +
  • [43] Paclitaxel in the treatment of hormone-refractory prostate cancer
    Smith, DC
    Pienta, KJ
    SEMINARS IN ONCOLOGY, 1999, 26 (01) : 109 - 111
  • [44] Treatment options for hormone-refractory prostate cancer
    Heidenreich, A
    Ohlmann, CH
    UROLOGE, 2005, 44 (11): : 1303 - +
  • [45] Hormone-refractory prostate cancer: Therapeutic approach
    Pepe, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Calabria, C.
    Laudani, A.
    Usset, A.
    Cusimano, M.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2005, 16 : 154 - 155
  • [46] Satraplatin in the treatment of hormone-refractory prostate cancer
    Sternberg, CN
    BJU INTERNATIONAL, 2005, 96 (07) : 990 - 994
  • [47] The role of bisphosphonates in hormone-refractory prostate cancer
    Fred Saad
    Pierre Karakiewicz
    Paul Perrotte
    World Journal of Urology, 2005, 23 : 14 - 18
  • [48] DocetaxelIn Hormone-Refractory Metastatic Prostate Cancer
    Kate McKeage
    Susan J. Keam
    Drugs, 2005, 65 : 2287 - 2294
  • [49] The role of endothelin in hormone-refractory prostate cancer
    Zonnenberg, BA
    Voest, EE
    EUROPEAN UROLOGY SUPPLEMENTS, 2003, 2 (03) : 9 - 14
  • [50] Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development
    Hsieh, Andrew C.
    Small, Eric J.
    Ryan, Charles J.
    LANCET ONCOLOGY, 2007, 8 (10): : 933 - 939